Fiche publication
Date publication
octobre 2025
Journal
BMJ open
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BONNOTTE Bernard
,
Dr FOURNEL Isabelle
,
Dr DEVILLIERS Hervé
Tous les auteurs :
Samson M, Fournel I, Bourredjem A, Cortier M, Galizzi E, Cransac A, Cladière C, Fleck C, Brayer M, Carpentier M, Alberini JL, Devilliers H, Bonnotte B
Lien Pubmed
Résumé
Giant cell arteritis (GCA) is a large-vessel vasculitis occurring in people aged over 50 years. Recent studies have shown that tocilizumab (TCZ), an anti-IL-6 receptor monoclonal antibody, is remarkably effective in treating GCA and allows significant dose sparing of glucocorticoids. However, it makes it difficult to monitor disease activity. Furthermore, treatment is often prolonged over 1 year due to the fear of relapse after stopping TCZ and/or the absence of an optimal discontinuation scheme.
Mots clés
Clinical Trial, INTERNAL MEDICINE, Randomized Controlled Trial
Référence
BMJ Open. 2025 10 9;15(10):e108115
